Technology

Clearlake and Insight reach $4.4B deal to take software maker Alteryx private

December 19, 2023

Alteryx, an Irvine, California-based software company developing data science and analytics products, today announced that it’s agreed to be acquired by private equity firms Clearlake Capital Group and Insight Partners in a deal worth $4.4 billion. Clearlake and Insight reportedly beat out Symphony Technology Group, another private equity firm, which Reuters reported several days ago […]

© 2023 TechCrunch. All rights reserved. For personal use only.

Developing climate solutions with green software

December 18, 2023
After years of committing to sustainable practices in his personal life from recycling to using cloth-based diapers, Asim Hussain, currently the director of green software and ecosystems at Intel, began to ask questions about the practices in his work: software development. Developers often asked if their software was secure enough, fast enough, or cost-effective enough…

The Download: a microbiome gold rush, and Eric Schmidt’s election misinformation plan

December 18, 2023
This is today’s edition of The Download, our weekday newsletter that provides a daily dose of what’s going on in the world of technology. The hunter-gatherer groups at the heart of a microbiome gold rush Over the last couple of decades, scientists have come to realize just how important the microbes that crawl all over us are…

Get ready to fight misinformation in 2024. Eric Schmidt has advice.

December 18, 2023
This article is from The Technocrat, MIT Technology Review’s weekly tech policy newsletter about power, politics, and Silicon Valley. To receive it in your inbox every Friday, sign up here. We’re already at that time of year when we start looking ahead to what’s coming in 2024. For Technocrat readers (and the rest of the…

The hunter-gatherer groups at the heart of a microbiome gold rush

December 18, 2023
We’re all teeming with microbes. We’ve got guts full of them, and they’re crawling all over our skin. These tiny, ancient life forms have evolved with us. And over the last couple of decades, scientists have come to realize just how important they are to our health and well-being. They help extract nutrients from our…

Democracies are fragile, and hardware is hard

December 16, 2023

Sometimes it’s important to state the obvious. That democracies are fragile but that technology can help. And also that crowdfunding isn’t always the best way to launch an innovative product.

© 2023 TechCrunch. All rights reserved. For personal use only.

When it comes to generative AI in the enterprise, CIOs are taking it slow

December 15, 2023

To hear the hype from vendors, you would think that the enterprise buyers are all in when it comes to generative AI, but like any newer technology, large companies tend to move cautiously. Throughout this year, as vendors feverishly announced new generative-AI fueled products, CIOs took note. Some companies have actually been looking to cut […]

© 2023 TechCrunch. All rights reserved. For personal use only.

Eric Schmidt has a 6-point plan for fighting election misinformation

December 15, 2023
The coming year will be one of seismic political shifts. Over 4 billion people will head to the polls in countries including the United States, Taiwan, India, and Indonesia, making 2024 the biggest election year in history. And election campaigns are using artificial intelligence in novel ways. Earlier this year in the US, the Republican…

The Download: beyond CRISPR, and OpenAI’s superalignment findings

December 15, 2023
This is today’s edition of The Download, our weekday newsletter that provides a daily dose of what’s going on in the world of technology. Vertex developed a CRISPR cure. It’s already on the hunt for something better. The company that just got approval to sell the first gene-editing treatment in history, for sickle-cell disease, is already looking…

Vertex developed a CRISPR cure. It’s already on the hunt for something better.

December 15, 2023
The company that just got approval to sell the first gene-editing treatment in history, for sickle-cell disease, is already looking for an ordinary drug that could take its place. Vertex Pharmaceuticals has a 50-person team working “to make a pill that doesn’t do gene editing at all,” says David Altshuler, head of research at the…